InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,815.03
(
0.03%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

crudeoil24

Send PM Follow Ignore
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

crudeoil24

Member Level

Re: $heff post# 83061

Tuesday, 10/21/2014 11:17:10 AM

Tuesday, October 21, 2014 11:17:10 AM

Post# of 97237
OREX UP 17% @ 4.75 The company received approval for its obesity drug Contrave on September 11, and they will be partnering with Takeda Pharmaceutical to launch sales in the coming weeks. While other company’s obesity drugs have had disappointing sales figures, the Merrill Lynch analysts feel that Takeda’s big 900 sales rep force could be a difference maker.

Merrill Lynch has a $9 price target on Orexigen, and the consensus target is even higher at $11.

DUKE BASKETBALL and NOTRE DAME FOOTBALL

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up